Alan Harris

Physician-Scientist Entrepreneur and Pharmaceutical Executive

Alan Harris, MD, PhD, FACP, FRCP is a Physician-Scientist Entrepreneur and Pharmaceutical Executive at Novartis, Schering-Plough- Merck, Pfizer, NPS, Radius, and Recordati with 30 years of success across a broad range of therapeutic areas from rare disease treatments to widely prescribed medicines (Zetia, Claritin, Nasonex).He completed the top-performing biotech IPO in 2014 as Chief Medical Officer (CMO) at Radius Health. At Novartis, he led the worldwide clinical development and approval of the first somatostatin analog, octreotide (Sandostatin ®, Novartis), for the treatment of malignant Neuroendocrine Tumors (NETs) and acromegaly generating peak sales of $1.6B/year. He was also involved in the development of the first somatostatin peptide-based diagnostic imaging agent (Octreoscan ®) for NETS and the Peptide Radionuclide Radiotherapy (PRRT) agent, Lutathera ®, while at Biosynthema acquired by AAA that was sold to Novartis for $3.9B. Alan has expertise in developing cancer biomarkers in hormone-related cancers. He oversaw as CMO the FDA approval of the bone forming agent Tymlos for the treatment of postmenopausal osteoporosis. He spearheaded, as CMO, at Recordati Rare Diseases, the $390M purchase of two endocrine drugs from Novartis. He founded two peptide therapeutics companies in Switzerland and the US and sold one to Amryt Pharmaceuticals/Chiesi. He founded the radiopharmaceuticals company Grafton Therapeutics focused on the development of next generation bispecific radiolabelled somatostatin analogs for the treatment of cancers Alan was awarded an MD from Strasbourg University School of Medicine, France, and a Ph.D. in Endocrinology University of Rotterdam. He was previously an associate Professor of Medicine at UCLA Cedars Sinai Medical Center and is currently an adjunct Professor of Medicine in the division of endocrinology at NYU Grossman School of Medicine.